23andMe directors resign as CEO seeks to take genetic ... - CBS News
WEB17 hours ago · PIX Now morning edition 9-20-24 11:09. All of 23andMe's independent directors resigned from its board this week, a rare move that marks the latest challenge for the genetic-testing company.
What happened to 23andMe? | CNN Business
WEB1 day ago · A version of this story appeared in CNN Business’ Nightcap newsletter. To get it in your inbox, sign up for free, here. New York CNN — The history of DNA-testing startup 23andMe reads like a ...
23andMe directors resign as the CEO of the genetic-testing ... - ABC News
WEB1 day ago · 23andMe, which went public in 2021, has struggled to find a profitable business model since. The company reported a net loss of $667 million for its last fiscal year, more than double the loss of ...
23andMe independent directors resign from board: Read the CEO …
WEB4 days ago · Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023. All seven independent ...
23andMe Board Resigns in New Blow to DNA-Testing Company
WEB3 days ago · Photo: David Paul Morris/Bloomberg News. All seven independent directors of DNA-testing company 23andMe ME -0.29% resigned Tuesday, following a protracted negotiation with founder and Chief ...
Independent Directors of 23andMe Resign from Board - Yahoo …
WEB3 days ago · SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the following letter to Anne Wojcicki, Chief ...
Wojcicki ‘Committed’ to Taking 23andMe Private as Board Quits
WEB3 days ago · September 17, 2024 at 9:22 PM EDT. Save. 23andMe Holding Co.co-founder and Chief Executive Officer Anne Wojcickitold employees that she remains committed to taking the genetic testing company ...
23andMe Therapeutics Announces Phase 2 Results for Two …
WEB6 days ago · SUNNYVALE, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from its Phase 1/2a clinical trial covering two new patient cohorts from 23ME-00610 (’610), a …
23andMe independent directors quit board over unsatisfactory …
WEB3 days ago · Wojcicki, who has been trying to take the company private since April, proposed to acquire all outstanding shares of 23andMe not owned by her or her affiliates for $0.40 per share, in July. A ...
23andMe CEO Wojcicki open to third-party takeover proposals …
WEBSep 11, 2024 · The genetic testing firm's shares were up 2.8% at $0.31 in extended trade. In July, Wojcicki, who has been trying to take the company private, proposed to acquire all outstanding shares of 23andMe ...
- Some results have been removed